IBRN - ETF AI Analysis
Top Page
iShares Neuroscience and Healthcare ETF (IBRN)
Rating:55Neutral
Price Target:―
Positive Factors
Strong Recent Fund Performance
The ETF has shown solid gains so far this year and over the past month, indicating positive recent momentum.
Several Strong-Performing Top Holdings
A number of the largest positions, such as Xenon, Alkermes, Centessa, and Praxis, have delivered strong year-to-date results that support the fund’s overall performance.
Targeted Exposure to Neuroscience and Healthcare
The fund’s heavy focus on health care and neuroscience companies offers concentrated exposure to a specialized growth area within the medical sector.
Negative Factors
High Sector Concentration in Health Care
With the vast majority of assets in health care, the ETF is heavily exposed to risks specific to that sector.
Underperforming Key Holdings
Some top positions, including PTC Therapeutics, Argenx, and Neurocrine, have shown weak year-to-date performance, which can drag on the fund’s returns.
Limited Geographic Diversification
The portfolio is dominated by U.S. companies, offering little diversification across international markets.
IBRN vs. SPDR S&P 500 ETF (SPY)
AUM5.31M
RegionGlobal
Expense Ratio0.47%
Beta1.12
IssueriShares
Inception DateAug 24, 2022
Dividend Yield0.95%
Asset ClassEquity
Index TrackedNYSE FactSet Global Neuro Biopharma and MedTech Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,184
30 Day Avg. Volume1,558
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
51.91Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering72
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IBRN Summary
The iShares Neuroscience and Healthcare ETF (IBRN) tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index, focusing on health care companies working on brain and nervous system treatments. It mainly holds U.S. drug and biotech firms, including names like Neurocrine and Alkermes, that are developing new medicines and medical technologies. An investor might consider this ETF for targeted growth potential in cutting-edge health care and to spread risk across many neuroscience-focused companies instead of picking just one stock. However, it is concentrated in a single, specialized sector, so its price can be very volatile and may rise or fall more than the overall market.
How much will it cost me?The iShares Neuroscience and Healthcare ETF (IBRN) has an expense ratio of 0.47%, which means you’ll pay $4.70 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused fund that requires more active management to target specific companies in the neuroscience and healthcare fields.
What would affect this ETF?The iShares Neuroscience and Healthcare ETF (IBRN) could benefit from growing global demand for advanced neurological treatments and breakthroughs in biotechnology, as well as increased funding for health care innovation. However, it may face challenges from regulatory hurdles in drug approvals, potential economic slowdowns impacting research budgets, and competition within the pharmaceutical and biotech sectors. Its global exposure and focus on cutting-edge companies provide opportunities but also expose it to risks tied to international market conditions.
IBRN Top 10 Holdings
IBRN is very much a one-theme story: it’s almost entirely health care, with a tight focus on neuroscience names from a global roster of biopharma and medtech players. Recent gains are being led by rising stars like Axsome Therapeutics and Neurocrine, which are helping pull the fund higher. Centessa has also been on a strong upswing, adding some extra fuel. On the flip side, Argenx and PTC Therapeutics have been more of a drag, reminding investors that this is a high-risk, high-reward corner of the market.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Axsome Therapeutics | 4.74% | $254.95K | $12.07B | 113.87% | 57 Neutral | |
| Alkermes | 4.59% | $246.82K | $7.03B | 35.09% | 80 Outperform | |
| Arrowhead Pharmaceuticals | 4.54% | $244.08K | $10.97B | 358.54% | 57 Neutral | |
| Xenon | 4.52% | $243.04K | $5.29B | 77.62% | 48 Neutral | |
| Neurocrine | 4.19% | $225.60K | $15.92B | 29.25% | 80 Outperform | |
| PTC Therapeutics | 4.10% | $220.41K | $6.13B | 51.14% | 72 Outperform | |
| Argenx Se | 3.88% | $208.89K | $51.51B | 43.02% | 79 Outperform | |
| Centessa Pharmaceuticals | 3.82% | $205.42K | $6.15B | 197.24% | 33 Underperform | |
| Praxis Precision Medicines | 3.79% | $203.86K | $9.76B | 741.69% | 58 Neutral | |
| Scholar Rock Holding | 3.73% | $200.45K | $5.91B | 59.24% | 50 Neutral |
IBRN Technical Analysis
Neutral
―
Price Trends
34.26
Negative
33.19
Positive
30.82
Positive
Market Momentum
0.15
Positive
41.65
Neutral
60.64
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IBRN, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 35.17, equal to the 50-day MA of 34.26, and equal to the 200-day MA of 30.82, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 41.65 is Neutral, neither overbought nor oversold. The STOCH value of 60.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IBRN.
IBRN Peer Comparison
Comparison Results
Performance Comparison
IBRN
iShares Neuroscience and Healthcare ETF
33.81
11.23
49.73%
HTEC
ROBO Global Healthcare Technology and Innovation ETF
―
―
―
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
PSIL
AdvisorShares Psychedelics ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents